Crinetics Pharmaceuticals Prepares for Q3 2025 Earnings Call

Crinetics Pharmaceuticals Announces Upcoming Earnings Release

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) is gearing up to disclose its financial performance for the third quarter of 2025. The announcement is scheduled for November 6, 2025, after the market wraps up for the day. Following this announcement, the management team will host a conference call at 4:30 p.m. ET, where they will delve into the financial results and offer insights into the company's ongoing business strategies.

Conference Call Details

Date and Time

Mark your calendars for Thursday, November 6, 2025, at 4:30 p.m. ET. This is an excellent opportunity for investors and curious minds alike to listen in on the latest developments directly from the company’s leadership.

How to Participate

To join the conference call, you can use the following numbers: for domestic participants, dial 1 833-470-1428, and for international attendees, the number is 1 646-844-6383. The access code you will need to enter is 166837. It's recommended to connect at least 15 minutes ahead of time to ensure a ready and thorough engagement.

Webcast Availability

For those who prefer a digital format, Crinetics Pharmaceuticals will also provide a live webcast of the conference call. Participants can access the webcast via a direct link provided by the company. Additionally, a recording of the webcast will be available afterward on the Investor Relations section of the Crinetics website, allowing for easy access and review.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a noteworthy player in the pharmaceutical sector, dedicated to advancing the treatment of endocrine diseases and related tumors through innovative, patient-centric science. Their efforts focus on the discovery and commercialization of novel therapies that target G-protein coupled receptors (GPCRs), utilizing small molecules designed with specific pharmacological properties.

Leading Products and Pipeline

The flagship product of Crinetics, PALSONIFY™ (paltusotine), has made a significant impact in treating adults with acromegaly, especially for those who have encountered challenges with surgical options. Currently in the spotlight, paltusotine is also under clinical investigation for carcinoid syndrome associated with neuroendocrine tumors. Remarkably, Crinetics is expanding its portfolio with over ten disclosed programs, including atumelnant, which is under late-stage development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome.

Investment Relations Contact

For investors seeking more information, they can reach out to Gayathri Diwakar, the Head of Investor Relations. The contact email is gdiwakar@crinetics.com, and the phone number is (858) 345-6340.

Media Inquiries

For any press-related questions or concerns, Natalie Badillo, the Head of Corporate Communications, can be contacted at nbadillo@crinetics.com or by calling (858) 345-6075. She can provide media representatives with the necessary information and support regarding Crinetics Pharmaceuticals.

Frequently Asked Questions

When is the earnings report for Crinetics Pharmaceuticals?

The earnings report for Crinetics Pharmaceuticals is set for November 6, 2025.

How can I participate in the conference call?

To participate, dial 1 833-470-1428 domestically or 1 646-844-6383 internationally, using access code 166837.

Where can I find the webcast of the call?

The webcast will be available through a direct link provided by the company on their website.

What is PALSONIFY and its significance?

PALSONIFY™ (paltusotine) is Crinetics' lead product, designed for treating acromegaly, offering a significant advancement in therapy options for affected adults.

Who should I contact for investor relations?

For investor relations inquiries, contact Gayathri Diwakar at gdiwakar@crinetics.com or call (858) 345-6340.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.